29 June 2020

• The US government announces that it has purchased over 90% of the remdesivir that Gilead will produce during the summer of 2020; the price per treatment course is fixed at $3,120 for private insurers and $2,340 for government-sponsored healthcare – and in high income countries with national health systems (although it is unclear how they will be able to access it). Sources 1,2
• China’s Central Military Commission approves the CanSino Ad5-nCoV vaccine for military use only; it is not clear whether vaccination will be mandatory or optional. Source

Return to the timeline